Updated data from a National Cancer Institute-sponsored clinical trial conducted by the Cancer and Leukemia Group (CALGB) was presented May 5 at the 13th International Myeloma Workshop in Paris, France. The phase III study evaluated the benefits of continuous, or maintenance, treatment with lenalidomide (Revlimid) following an autologous stem-cell transplant in newly diagnosed multiple myeloma patients and found that lenalidomide delays time to disease progression and improves overall survival compared to placebo... 
More...
More...